Biotech Values

[10nisman]

I would submit that the tepid investor response to the BAX deal (so far) is not due to a deficiency in the partnership’s financial terms, but rather to skepticism that MNTA can accomplish what it says it can accomplish with respect to interchangeability.

I completely agree and the reason why I (and likely most) were hoping MNTA could get mC approved on a fully interchangeable basis prior to inking a deal.